AAAAAA

   
Results: 1-17 |
Results: 17
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. (vol 6, pg 1176, 2000)
Authors: Kappos, L Comi, G Panitch, H Oger, J Antel, J Conlon, P Steinman, L
Citation: L. Kappos et al., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. (vol 6, pg 1176, 2000), NAT MED, 7(1), 2001, pp. 129-129
Potassium channel antibodies in two patients with reversible limbic encephalitis
Authors: Buckley, C Oger, J Clover, L Tuzun, E Carpenter, K Jackson, M Vincent, A
Citation: C. Buckley et al., Potassium channel antibodies in two patients with reversible limbic encephalitis, ANN NEUROL, 50(1), 2001, pp. 73-78
In myasthenia gravis cells from atrophic thymus secrete acetylcholine receptor antibodies
Authors: Katzberg, HD Aziz, T Oger, J
Citation: Hd. Katzberg et al., In myasthenia gravis cells from atrophic thymus secrete acetylcholine receptor antibodies, NEUROLOGY, 56(4), 2001, pp. 572-573
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Authors: Francis, G Hughes, R King, J Mitchell, P Joubert, J McLeod, J Parker, G Pollard, J Sindic, CJM Duprez, T Medaer, R Broeckx, J Vanroose, E Carton, H Wilms, G Rice, G Ebers, G Lee, DH Freedman, M Nelson, R Rabinovitch, H Christie, S Avruch, L Oger, J Paty, DW Li, D Wikstrom, J Salonen, OLM Panelius, M Eralinna, J Sonninen, P Rieckmann, P Hahn, D Flachenecker, P Hartung, HP Uitdehaag, B Bertelsmann, FW Barkhof, F Hommes, OR Jongen, PJH Van Doorn, PA Tanghe, HLG Sandberg-Wollheim, M Larsson, EM Lonntoft, M Sallerfors, S Kappos, L Lienert, C Radu, EW Chofflon, M Roth, S Castillo, V Schwieger, AF Hughes, RAC Clews, AM Bingham, JB Barnes, D Clifton, AG Stoy, N Bates, D Coulthard, A Blumhardt, LD Evans, SM Jaspan, T Palace, J Newsom-Davis, JM Byrne, JV Quaghebeur, G Li, DKB Paty, DW Zhao, GJ Riddehough, A Rhodes, B
Citation: G. Francis et al., PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS, NEUROLOGY, 56(12), 2001, pp. 1628-1636
Randomized controlled trial of interferon-beta-1a in secondary progressiveMS - Clinical results
Authors: King, J McLeod, J Gonsette, RE Duquette, P Ebers, G Rice, G Francis, G Lapierre, Y Freedman, MS Oger, J Paty, D Sorensen, PS Pelletier, J Hommes, OR Jongen, PJH Sanders, EACM Andersen, O Wollheim-Sandberg, M Chofflon, M Bates, D Barnes, D Blumhardt, LD Hawkins, C Hughes, RAC Palace, J Newsom-Davis, JM Young, CA Ammoury, N Bacchi, M Francis, G Galazka, A Hyde, R Shah, S
Citation: J. King et al., Randomized controlled trial of interferon-beta-1a in secondary progressiveMS - Clinical results, NEUROLOGY, 56(11), 2001, pp. 1496-1504
Interferon beta-1 a for optic neuritis patients at high risk for multiple sclerosis
Authors: O'Connor, P Fleming, P Gray, T Jacobs, L Miller, C Munschauer, F Kinkel, RP Bolibrush, D Cohen, J Freedman, M Webb, U Rabinowicz, H Metz, LM Patry, D Yeung, M Peters, S Hashimoto, S Morrison, W Oger, J Panitch, H Costello, K Bever, C Stuart, W Court, D Stuart, D Tornatore, C Bartlett, D Richert, J Duquette, P Dubois, R Bernier, G Scott, T Pappert, L Brillman, J Felton, W Anderson, T Astruc, J Rose, J Kline, J Burns, J Murray, T Weldon, P Bhan, V Maxner, CE Wall, M Vining, L Grabowski, T Apatoff, B Arapello, K Friedman, J Galetta, S Pfohl, D Liu, G Rice, G Bental, T Mandalfino, P Eggenberger, E Snider, D Kaufman, D Guarnaccia, J Shepard, M Goldstein, J Reiss, M Carter, E Glista, G Rolak, L Scheller, L Jacobson, D Warner, J Goodman, A Petrie, M Mattson, D Karlin, K Wallin, A Stefoski, D Brod, S Cerretta, E Wolinsky, J Arnold, D Arnoutelis, R Durcan, L Kupersmith, M Cappolino, L Herbert, J Rosenberg, J McHugh, D Blumenfeld, A Smith, C Kuder, D Hamilton, S Thurston, S McGee, J O'Bannon, J Kaufman, M Butler, M Putnam, S Rammohan, K Siffort, A Lynn, J Selhorst, J Holzemer, E Hayat, G Tselis, A Coon, C Lisak, R Wray, S Sexton, P Lehrich, J Cook, S Jotkowitz, A Bansil, S Newman, N Brown, J Pennell, P Gilmore, J Carter, J Buckner, J Caselli, R Kerson, L Camasso, M Donneief, G Cooper, J Richardson, B Kung, C Goodwin, J Johnson, T Gulati, A Hedges, T Yardley, C Tran, T Brown, W Ehrenberg, B Horowitz, S Bonnett, A Burger, R Javerbaum, J Griffin, C Whaley, RJ Jeffery, D Jackson, SE Bastings, E Kasper, L Ryan, K Bernat, J Mass, M Hanel, SC Bourdette, D Guy, J Wilson, M Greer, M Lucchinetti, C Botten, M Noseworthy, J Walker, A Muntz, B Tyor, W Simon, J Meyer, M Leek, R Gustafson, C Singel, D Quandt, B Miller, DE Coombs, B Cajade-Law, A Lajaunie, M Escott, E Miller, A Richert, J Cohen, J Vollmer, T Oger, J Jacobs, L Beck, R Kinkel, RP Brownscheidle, C Murray, TJ Simon, J Antel, J Myers, L Birnbaum, G Reingold, S Burde, R Sibley, W Ware, J Blanchard, N Lloyd, K Park, H Sandrock, A Simonian, N Slasor, P Votruba, F White, K Beck, R Chandler, DL Cole, S Felton, W Galetta, S Jacobs, L Kinkel, RP Kupersmith, M Murray, TJ Newman, N Sandrock, A Simon, J Simonian, N
Citation: P. O'Connor et al., Interferon beta-1 a for optic neuritis patients at high risk for multiple sclerosis, AM J OPHTH, 132(4), 2001, pp. 463-471
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
Authors: Kappos, L Comi, G Panitch, H Oger, J Antel, J Conlon, P Steinman, L
Citation: L. Kappos et al., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial, NAT MED, 6(10), 2000, pp. 1176-1182
A pathology-MRI study of the short-T2 component in formalin-fixed multiplesclerosis brain
Authors: Moore, GRW Leung, E MacKay, AL Vavasour, IM Whittall, KP Cover, KS Li, DKB Hashimoto, SA Oger, J Sprinkle, TJ Paty, DW
Citation: Grw. Moore et al., A pathology-MRI study of the short-T2 component in formalin-fixed multiplesclerosis brain, NEUROLOGY, 55(10), 2000, pp. 1506-1510
Analysis of effector CD4 (OX-40(+)) and CD8 (CD45RA(+) CD27(-)) T lymphocytes in active multiple sclerosis
Authors: Hintzen, RQ Pot, K Paty, D Oger, J
Citation: Rq. Hintzen et al., Analysis of effector CD4 (OX-40(+)) and CD8 (CD45RA(+) CD27(-)) T lymphocytes in active multiple sclerosis, ACT NEUR SC, 101(1), 2000, pp. 57-60
Neutralising antibodies to interferon-beta in the treatment of multiple sclerosis - Cause for concern?
Authors: Paszner, B Petkau, J Oger, J
Citation: B. Paszner et al., Neutralising antibodies to interferon-beta in the treatment of multiple sclerosis - Cause for concern?, CNS DRUGS, 11(3), 1999, pp. 225-243
Consensus statement of the Canadian MS clinics network on: The use of disease modifying agents in multiple sclerosis
Authors: Oger, J Freedman, M
Citation: J. Oger et M. Freedman, Consensus statement of the Canadian MS clinics network on: The use of disease modifying agents in multiple sclerosis, CAN J NEUR, 26(4), 1999, pp. 274-274
Treatment with interferon beta-1b improves quality of life in multiple sclerosis
Authors: Rice, GP Oger, J Duquette, P Francis, GS Belanger, M Laplante, S Grenier, JF
Citation: Gp. Rice et al., Treatment with interferon beta-1b improves quality of life in multiple sclerosis, CAN J NEUR, 26(4), 1999, pp. 276-282
Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients
Authors: Benny, WB Sutton, DMC Oger, J Bril, V McAteer, MJ Rock, G
Citation: Wb. Benny et al., Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients, TRANSFUSION, 39(7), 1999, pp. 682-687
Enhanced adherence of endothelial cells to blood mononuclear cells in HAM/TSP. Predominant role of ICAM-1.
Authors: Cabre, P Al-Fahim, A Oger, J
Citation: P. Cabre et al., Enhanced adherence of endothelial cells to blood mononuclear cells in HAM/TSP. Predominant role of ICAM-1., REV NEUROL, 155(4), 1999, pp. 273-279
The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b
Authors: Rice, GPA Paszner, B Oger, J Lesaux, J Paty, D Ebers, G
Citation: Gpa. Rice et al., The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b, NEUROLOGY, 52(6), 1999, pp. 1277-1279
Cerebrospinal fluid concentrations of soluble CD27 in HTLV-I associated myelopathy and multiple sclerosis
Authors: Hintzen, RQ Paty, D Oger, J
Citation: Rq. Hintzen et al., Cerebrospinal fluid concentrations of soluble CD27 in HTLV-I associated myelopathy and multiple sclerosis, J NE NE PSY, 66(6), 1999, pp. 791-793
Blood mononuclear cells in patients with HTLV-I-associated myelopathy: Lymphocytes are highly activated and adhesion to endothelial cells is increased
Authors: Al-Fahim, A Cabre, P Kastrukoff, L Dorovini-Zis, K Oger, J
Citation: A. Al-fahim et al., Blood mononuclear cells in patients with HTLV-I-associated myelopathy: Lymphocytes are highly activated and adhesion to endothelial cells is increased, CELL IMMUN, 198(1), 1999, pp. 1-10
Risultati: 1-17 |